Results 31 to 40 of about 5,838,181 (363)

Protein tyrosine phosphatases in multiple myeloma

Cancer Letters, 2021
Many cell signaling pathways are activated or deactivated by protein tyrosine phosphorylation and dephosphorylation, catalyzed by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), respectively. Even though PTPs are as important as PTKs in this process, their role has been neglected for a long time.
Pegah Abdollahi, Maja Köhn, Magne Børset   +2 more
openaire   +3 more sources

MAGE-C1 gene and mage-c1 protein expression comparison in primary multiple myeloma patients

Онкогематология, 2022
Background. Nowadays, hematology is a dynamically developing science due to the in-depth study of the molecular mechanisms of a particular disease. A better understanding of oncohematological diseases biology makes it possible to synthesize new targeted ...
E. A. Makunina, L. P. Mendeleeva, V. L. Surin, M. V. Soloviev, M. V. Firsova, A. M. Kovrigina, A. A. Sherstnev, I. V. Gal’tseva, Y. O. Davydova, S. M. Kulikov   +9 more
doaj   +1 more source

Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma

CPT: Pharmacometrics & Systems Pharmacology, 2019
The heterogeneous polyclonal nature of multiple myeloma complicates the identification of protein biomarkers predictive of drug response. In this study, a pharmacodynamic systems modeling approach was used to link in vitro bortezomib exposure and myeloma
Vidya Ramakrishnan, Donald E. Mager
doaj   +1 more source

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Haematologica, 2012
Background Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment.
Silvia C. W. Ling, Edwin K. K. Lau, Ammira Al-Shabeeb, Angela Nikolic, Albert Catalano, Harry Iland, Noemi Horvath, P. Joy Ho, Simon Harrison, Shaun Fleming, Douglas E. Joshua, John D. Allen   +11 more
doaj   +1 more source

Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma

Frontiers in Oncology, 2022
Multiple myeloma grows by establishing multiple interactions with bone marrow cells. These include expansion of myeloid-derived suppressor cells, which drive immunoevasion via mechanisms that include arginase-1-driven depletion of L-arginine, thus ...
Matteo Trudu, Matteo Trudu, Laura Oliva, Ugo Orfanelli, Alessandra Romano, Alessandra Romano, Francesco Di Raimondo, Francesca Sanvito, Maurilio Ponzoni, Maurilio Ponzoni, Simone Cenci, Simone Cenci   +11 more
doaj   +1 more source

A Rare Case of Multiple Myeloma with Biclonal Gammopathy [PDF]

Journal of Clinical and Diagnostic Research, 2016
Multiple myeloma is a debilitating malignancy arising from plasma cells. These malignant plasma cells called myeloma cells proliferate and infiltrate the bone marrow.
Abhik Banerjee, Kshama Pimpalgaonkar, Alap Lukiyas Christy   +2 more
doaj   +1 more source

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Haematologica, 2015
Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.
Marianne Kraus, Juergen Bader, Paul P. Geurink, Emily S. Weyburne, Anne C. Mirabella, Tobias Silzle, Tamer B. Shabaneh, Wouter A. van der Linden, Gerjan de Bruin, Sarah R. Haile, Eva van Rooden, Christina Appenzeller, Nan Li, Alexei F. Kisselev, Herman Overkleeft, Christoph Driessen   +15 more
doaj   +1 more source

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Blood Cancer Journal
Multiple myeloma is a genetically complex and heterogenous malignancy with a 5-year survival rate of approximately 60%. Despite advances in therapy, patients experience cycles of remission and relapse, with each successive line of therapy associated with
P. Rodríguez-Otero, N. W. van de Donk, K. Pillarisetti, Ingrid Cornax, D. Vishwamitra, Kathleen S. Gray, B. Hilder, J. Tolbert, Thomas Renaud, T. Masterson, Christoph Heuck, Colleen Kane, R. Verona, P. Moreau, Nizar J. Bahlis, A. Chari   +15 more
semanticscholar   +1 more source

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

Journal of Immunotherapy for Cancer, 2015
BackgroundMultiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the bone marrow and is generally considered to be an incurable disease. Successful treatments will likely require multi-faceted approaches incorporating
Weiqing Jing, J. Gershan, James J. Weber, Dominique Tlomak, L. McOlash, C. Sabatos-Peyton, Bryon D. Johnson   +6 more
semanticscholar   +1 more source

A Case Report of Atypical Presentation of Multiple Myeloma on Serum Protein Electrophoresis [PDF]

Journal of Krishna Institute of Medical Sciences University, 2018
Multiple myeloma is a group of B-cell disorders resulting in the secretion of a specific and unique monoclonal immunoglobulin (M-protein). Protein electrophoresis is advised whenever multiple myeloma is suspected.
Pooja P. Padasal, Anil Malleshappa
doaj